What is HC Wainwright's Estimate for ODTX Q1 Earnings?

Key Points

• HC Wainwright forecasts Q1 2027 EPS of ($1.27) for Odyssey Therapeutics and estimates losses of ($1.29) in Q2 and Q3, and ($1.28) in Q4.
• HC Wainwright reiterated a Buy rating and $40 price target. Analysts overall give ODTX a “Moderate Buy” consensus rating, with a consensus target of $34.67.
• ODTX shares opened at $19.23; the stock has traded between $15.10 and $29.05 over the past year.

Odyssey Therapeutics, Inc. (NASDAQ:ODTX - Free Report) - Equities researchers at HC Wainwright issued their Q1 2027 earnings per share estimates for shares of Odyssey Therapeutics in a research report issued on Friday, November 6th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings per share of ($1.27) for the quarter. HC Wainwright currently has a "Buy" rating and a $40.00 price objective on the stock. The consensus estimate for Odyssey Therapeutics' current full-year earnings is ($6.18) per share. HC Wainwright also issued estimates for Odyssey Therapeutics' Q2 2027 earnings at ($1.29) EPS, Q3 2027 earnings at ($1.29) EPS and Q4 2027 earnings at ($1.28) EPS.

ODTX has been the topic of several other research reports. Raymond James Financial started coverage on shares of Odyssey Therapeutics in a report on Thursday, October 8th. They issued an "outperform" rating and a $42.00 price target on the stock. Weiss Ratings started coverage on Odyssey Therapeutics in a research note on Tuesday, August 11th. They issued a "sell (d+)" rating on the stock. UBS Group began coverage on Odyssey Therapeutics in a research note on Monday, October 12th. They issued a "buy" rating and a $27.00 price objective on the stock. Finally, JPMorgan Chase & Co. increased their target price on Odyssey Therapeutics from $26.00 to $29.00 and gave the stock an "overweight" rating in a report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $34.67.

Odyssey Therapeutics Stock Performance

Shares of ODTX stock opened at $19.23 on Monday. The company has a market capitalization of $924.39 million and a PE ratio of -2.84. Odyssey Therapeutics has a one year low of $15.10 and a one year high of $29.05. The business has a fifty day moving average price of $21.18.

Odyssey Therapeutics (NASDAQ:ODTX - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.74) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Odyssey Therapeutics

Hedge funds have recently made changes to their positions in the company. Citadel Advisors LLC bought a new position in Odyssey Therapeutics during the 2nd quarter valued at about $4,162,000. Aberdeen Group plc boosted its position in Odyssey Therapeutics by 4.7% in the third quarter. Aberdeen Group plc now owns 172,771 shares of the company's stock valued at $3,839,000 after buying an additional 7,771 shares in the last quarter. State Street Corp bought a new stake in Odyssey Therapeutics during the second quarter worth about $1,477,000. The Manufacturers Life Insurance Company bought a new stake in Odyssey Therapeutics during the second quarter worth about $601,000. Finally, Russell Investments Group Ltd. bought a new stake in Odyssey Therapeutics during the third quarter worth about $28,000.

Odyssey Therapeutics Company Profile

Odyssey Therapeutics is a clinical-stage biotechnology company focused on discovering and developing precision medicines for immune-mediated diseases and cancer. The company combines computational biology, functional genomics, and experimental drug discovery to identify therapies directed at disease-driving biological pathways.

Its research programs are centered primarily on small-molecule medicines and other targeted approaches intended to modulate the immune system or address vulnerabilities in cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.